The EBMT/EHA CAR-T Cell Handbook.
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing AG,
2022.
|
| Edition: | 1st ed. |
| Subjects: | |
| Online Access: | Click to View |
Table of Contents:
- Intro
- Preface
- Contents
- Part I: The Science Behind CAR-T Cells
- 1: Structure of and Signalling Through Chimeric Antigen Receptor
- References
- 2: Genetic Engineering of Autologous or Allogeneic Immune Effector Cells
- References
- 3: What Defines a Good Tumour Antigen?
- Tumour-Specific Antigens (TSAs)
- Multiple Tumour Antigens Resulting in a 'Tumour-Specific Phenotype'
- Lineage-Specific and Differentiation Antigens
- Lineage-Specific Polymorphic/Heterogeneic Antigens
- References
- 4: Tumour Escape from CAR-T Cells
- Immune Escape and CAR-T Cell Resistance Related to Antigen Loss
- Immune Dysfunction and Exhaustion of CAR-T Cells
- Microenvironment-Mediated Tumour Resistance to CAR-T Cells
- References
- 5: CART Initiatives in Europe
- References
- Part II: Manufacturing CAR-T Cells: The Supply Chain
- 6: Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment
- Introduction
- References
- 7: Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility
- Definition
- Administration
- Patients Treated with CAR-T Cells: New Missions for the Hospital Pharmacist
- References
- 8: Point-of-Care Production of CAR-T Cells
- GMP Vector Production
- Manufacturing CAR-T Cells
- References
- 9: Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells
- Strategies to Avoid Graft Versus Host Disease (GvHD)
- Genome Edited αβTCR-Deleted T Cells
- Virus-Specific T (VST) Cells
- Alternative Immune Effector Cells
- Strategies to Avoid Host-Mediated Rejection of Allogeneic Immune Cells
- Resistance to Lymphodepletion and Immunosuppression
- Removal of HLA for Evading Host Immunity
- Manufacturing Aspects of 'Off-the-Shelf' CARs
- References.
- Part III: Clinical Indications for CAR-T Cells
- 10: Paediatric Acute Lymphoblastic Leukaemia (ALL)
- References
- 11: Adult Acute Lymphoblastic Leukaemia
- CAR-T Cell Therapy for Adult ALL
- Consolidation After CAR-T Cell Therapy
- Relapse After CAR-T Cell Therapy
- References
- 12: Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma
- Patient Population to Consider: Lymphoma-Specific Aspects
- Treatment History
- Remission Status and Tumour Bulk Prior to CAR-T Cell Infusion
- Histology
- Patient Population to Consider: Patient-Specific Aspects
- Alternative Treatments
- References
- 13: Mantle Cell Lymphoma
- Clinical Indications for CAR-T Cells
- Critical Evaluation
- References
- 14: Chronic Lymphocytic Leukaemia
- Clinical Development of CAR-T Cells for CLL
- Current Indications for CAR-T Cells in the Treatment Landscape of CLL
- Prospective Studies of Autologous Anti-CD19 CAR-T Cell Therapy for CLL
- References
- 15: Indolent Lymphomas
- References
- 16: Multiple Myeloma
- References
- 17: Developments in Other Haematological Malignancies: Other Lymphoid Malignancies
- Target Antigens
- CAR-T Development in T Cell Malignancies
- Bibliography
- 18: Myeloid Malignancies
- Single or Dual Antigen Targeting?
- Molecular Engineering of the Chimeric Receptor and Alternative Cell Sources
- References
- 19: Developments in Solid Tumours
- References
- Part IV: Clinical Management of Patients Treated with CAR-T Cells
- 20: Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia
- References
- Further Reading
- 21: Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL
- The Importance of the Bridge
- Is There a Place for Immunotherapy?
- References
- 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma.
- To Bridge or Not to Bridge in Relapsed and Refractory (R/R) Aggressive B-Cell Lymphoma?
- Which Bridging Therapy?
- Response Rate to Bridging Therapy and Subsequent CAR-T Cell Therapy
- References
- 23: Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
- References
- 24: Bridging Chemotherapy: Multiple Myeloma
- Should All MM Patients Receive Bridging Therapy?
- Timeframe to Use Bridging Treatments
- Choice of Treatment
- References
- 25: Lymphodepleting Conditioning Regimens
- References
- 26: Management of Cytokine Release Syndrome (CRS) and HLH
- Cytokine Release Syndrome (CRS)
- Definition and Occurrence
- Diagnosis
- Clinical Symptoms, Laboratory Diagnosis, Differential Diagnosis, and Predictive Factors
- Management
- Anti-Cytokines
- Steroids
- Antibiotics
- sHLH/MAS
- References
- 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
- Further Reading
- 28: Management of Hypogammaglobulinaemia and B-Cell Aplasia
- References
- 29: Management of Myelotoxicity (Aplasia) and Infectious Complications
- References
- 30: Management of Other Toxicities
- Considerations for Patients Undergoing CAR-T Cell Therapy
- References
- 31: ICU
- References
- 32: Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia
- Management of Relapsed B-ALL After CD19 CAR-T Cell Therapy
- CD19-Positive Disease After CD19 CAR-T Cell Therapy
- CD19-Negative Disease After CD19 CAR-T Cell Therapy
- References
- 33: Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma
- References
- 34: Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma
- References
- 35: Immune Monitoring
- Molecular Monitoring of CAR-T Cells via Digital PCR (dPCR)
- Flow Cytometry Monitoring of CAR-T Cells.
- Monitoring of Additional Immune Parameters (Non-CAR-T, B, and NK Cells and Cytokines)
- References
- 36: Long-Term Follow-Up and Late Effects
- Follow-Up and Programmes
- Post-authorisation Safety Surveillance (PASS)
- JACIE
- References
- Part V: Access to CAR-T Cells
- 37: The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers
- Current Framework
- Hospital Exemption
- Role of Academia
- Health Technology Assessment
- Future Focus
- Centre Qualification by Competent Authorities and Manufacturers
- Shared Goals
- Centre Assessment
- Centre Auditing
- Centre Training
- References
- 38: How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified?
- References
- 39: Educational Needs for Physicians
- References
- 40: Education Needs for Nurses in Adult and Paediatric Units
- Apheresis and Cell Collection
- Cell Infusion
- Patient Monitoring
- Toxicity Management
- Discharge
- Long-Term Follow Up
- Paediatric Considerations
- References
- 41: Role of Pharmacists
- References
- 42: Educational Needs for Cell Processing Facility Personnel
- 43: GoCART
- 44: Patient Referral
- References
- 45: Treatment Coverage and Reimbursement
- 46: The Value of CAR-T-cell Immunotherapy in Cancer
- References
- 47: What do Patients Want? The Importance of Patient-reported Outcomes
- References.